Switching to sucroferric oxyhydroxide from other phosphate binders might decrease hospital admissions among patients with persistent hyperphosphatemia, according to new research reported at Kidney Week 2020 Reimagined, a virtual meeting of the American Society of Nephrology.
In a retrospective study of 1076 patients with hyperphosphatemia (serum phosphate exceeding 5.5 mg/dL) for 3 months despite treatment with sevelamer carbonate, 319 were switched to sucroferric oxyhydroxide monotherapy and 757 to calcium acetate, lanthanum carbonate, or ferric citrate alone or in addition to sevelamer carbonate. Patients switched to sucroferric oxyhydroxide monotherapy had a 15% reduction in hospitalizations or 27 fewer all-cause hospital admissions per 100 patient-years compared with patients receiving other phosphate binder therapy (152.7 vs 179.8 per 100 patient-years, respectively), Sagar U. Nigwekar, MD, of Massachusetts General Hospital in Boston, Massachusetts, and colleagues reported in a poster presentation. The study found no significant differences in length of hospital admissions between patients who switched to sucroferric oxyhydroxide and patients who were prescribed other phosphate binders.
In their analyses, the investigators adjusted for dialysis vintage, congestive heart failure status, serum phosphorus levels and categories, and intact parathyroid hormone levels and categories.
Continue Reading
“This study provides one of the earliest suggestions that treatment of hyperphosphatemia with sucroferric oxyhydroxide, compared to other phosphate binders, may provide a reduction in the hospitalization rate and calls for future prospective studies to confirm this critical observation,” Dr Nigwekar said. “Prospective studies are needed to confirm the study findings.”
Disclosure: This clinical trial was supported by Fresenius Medical Care. Please see the original reference for a full list of authors’ disclosures.
Reference
Nigwekar SU, Parameswaran V, Ficociello L, Mullon C, Anger MS, Kossmann RJ. Hospital admission rates among hemodialysis patients with persistent hyperphosphatemia who were prescribed changes in phosphate binder treatment: a retrospective analysis of real-world data. Presented at: Kidney Week 2020 Reimagined, October 19-25, 2020. Poster PO0370.
